GeneHealth - Your precision medicine

Abetalipoproteinemia

Disease Details

Family Health Simplified

Buy Membership

Description: Abetalipoproteinemia is a rare genetic disorder characterized by the inability to properly absorb dietary fats, cholesterol, and fat-soluble vitamins due to the absence of apolipoprotein B-containing lipoproteins.
Type: Abetalipoproteinemia is a rare inherited disorder. Its genetic transmission is autosomal recessive.
Signs And Symptoms: Abetalipoproteinemia is a rare inherited disorder affecting the absorption of dietary fats, cholesterol, and fat-soluble vitamins. Here are the signs and symptoms:

1. **Neurological Symptoms:**
- Progressive ataxia (loss of coordination)
- Peripheral neuropathy (nerve damage causing weakness and pain)
- Retinitis pigmentosa (degeneration of the retina, leading to vision problems)

2. **Gastrointestinal Symptoms:**
- Steatorrhea (fatty, foul-smelling stools)
- Chronic diarrhea

3. **Growth and Development:**
- Failure to thrive in infants
- Developmental delays

4. **Musculoskeletal Symptoms:**
- Muscle weakness
- Loss of muscle mass

5. **Hematological Symptoms:**
- Acanthocytosis (presence of abnormally shaped red blood cells)
- Anemia (low red blood cell count)

6. **Other Symptoms:**
- Fat-soluble vitamin deficiencies (e.g., vitamins A, D, E, and K) leading to various complications such as night blindness, osteoporosis, and coagulopathy (bleeding disorders).
Prognosis: Prognosis can vary heavily based on the severity of the neurological dysfunction. If treatment is initiated early in disease the neurologic sequelae may be reversed and further deterioration can be prevented. Long-term outlook is reasonably good for most people when diagnosed and treated early. A case study presented a female patient diagnosed at the age of 11. Despite the relatively late diagnosis, the patient married and at the age of 34, gave birth to a full-term healthy infant. Her medication included vitamin K 10 mg twice a week, beta-carotene 40,000 IU daily, vitamin A 10,000 IU daily, vitamin E 400 IU daily, vitamins B6 and B12, calcium, magnesium and eye drops.Prolonged vitamin deficiencies can further compromise health. Specifically, a prolonged vitamin E deficiency can lead to the development of limiting ataxia and gait disturbances. Some individuals may develop retinal degeneration and blindness. If left untreated, the condition may lead to death.
Onset: Abetalipoproteinemia typically presents during infancy or early childhood. It is a rare inherited disorder that affects fat absorption and results in deficiencies of fat-soluble vitamins.
Prevalence: The prevalence of abetalipoproteinemia is very rare, estimated to be less than 1 in 1,000,000 people.
Epidemiology: Abetalipoproteinemia is an extremely rare genetic disorder, with an estimated prevalence of less than 1 in 1,000,000 individuals. It is inherited in an autosomal recessive manner, resulting from mutations in the MTTP gene, which leads to impaired fat absorption and metabolism. The condition is typically diagnosed in infancy or early childhood due to symptoms such as steatorrhea, failure to thrive, and neurological issues. The rarity of the condition makes precise epidemiological data limited.
Intractability: Abetalipoproteinemia is considered intractable because it is a rare genetic disorder without a cure. The management of the disease focuses on dietary modifications and supplementation to control symptoms and prevent complications. Lifelong adherence to these interventions is necessary for managing the condition effectively.
Disease Severity: Abetalipoproteinemia is generally severe and manifests from infancy. It can lead to growth failure, neurological deficits, and fat malabsorption. Early diagnosis and proper dietary management are crucial to manage the symptoms and improve the quality of life.
Healthcare Professionals: Disease Ontology ID - DOID:1386
Pathophysiology: Abetalipoproteinemia, also known as Bassen-Kornzweig disease, is a rare inherited disorder characterized by the body's inability to fully absorb dietary fats, cholesterol, and fat-soluble vitamins. The pathophysiology of abetalipoproteinemia involves a genetic mutation in the MTTP (microsomal triglyceride transfer protein) gene. This mutation leads to a deficiency or dysfunction of the MTTP enzyme, which is critical for the proper assembly and secretion of apolipoprotein B-containing lipoproteins in the liver and intestines. Without functional MTTP, chylomicrons and very low-density lipoproteins (VLDLs) cannot be formed, leading to extremely low levels of lipoproteins in the blood and subsequent fat malabsorption. This results in various clinical manifestations such as steatorrhea, acanthocytosis, neurological abnormalities, and deficiencies in fat-soluble vitamins (A, D, E, and K).
Carrier Status: Carrier status for abetalipoproteinemia typically means an individual has one mutated copy of the MTTP gene and one normal copy. Carriers usually do not exhibit symptoms of the disease, as abetalipoproteinemia follows an autosomal recessive inheritance pattern.
Mechanism: Abetalipoproteinemia effects multiple physiological systems, the two most common being the nervous and the skeletal. Disruption of nervous function includes loss of reflexes, speech impairments, tremors or involuntary motor tics, or peripheral neuropathy (damage to the nerves outside of the brain and spinal cord). Peripheral neuropathy causes loss of sensation, weakness or numbness and pain in the extremities through stabbing, burning, or tingling sensations. Skeletal system developments often include lordosis, kyphoscoliosis, or pes cavus. Individuals often have abnormal bleeding due to the difficulty of forming clots.Additional complications of the diseases if not properly treated include blindness, mental deterioration, ataxia, loss of peripheral nerve function.
Treatment: Treatment normally consists of rigorous dieting, involving massive amounts of vitamin E. High-dose Vitamin E therapy helps the body restore and produce lipoproteins, which people with abetalipoproteinemia usually lack. Vitamin E also helps keep skin and eyes healthy; studies show that many affected males will have vision problems later on in life. Common additional supplementation includes medium chain fatty acids and linoleic acid. Treatments also aim to slow the progression of nervous system abnormalities. Developmental coordination disorder and muscle weakness are usually treated with physiotherapy or occupational therapy. Dietary restriction of triglycerides has also been useful. Nutritionists often work with medical professionals to design appropriate dietary treatments for their patients.
Compassionate Use Treatment: Abetalipoproteinemia is a rare genetic disorder affecting lipid metabolism. For compassionate use and off-label or experimental treatments, the following may be considered:

1. **Vitamin E Supplementation**: High doses of vitamin E are typically used to manage and mitigate the neurological symptoms associated with this condition, although this is not a cure. The aim is to counteract oxidative damage due to lipid transport deficiencies.

2. **Fat-Soluble Vitamins**: Supplementation with other fat-soluble vitamins (A, D, and K) may also be necessary to correct deficiencies and prevent associated complications, especially those related to vision and blood clotting.

3. **Lomitapide**: Although primarily approved for Homozygous Familial Hypercholesterolemia, lomitapide has been investigated off-label for managing abetalipoproteinemia to reduce fat accumulation in the liver by inhibiting the microsomal triglyceride transfer protein (MTP).

4. **Gene Therapy**: Experimental approaches involving gene therapy are under investigation, aiming to correct the genetic defect causing abetalipoproteinemia.

5. **mRNA-based Therapies**: Similar to gene therapy, mRNA-based approaches are being researched to supplement the deficient proteins caused by the genetic mutations.

Patients need to be under the care of a specialist for appropriate management and monitoring due to the complexity and rarity of the disease.
Lifestyle Recommendations: Lifestyle recommendations for managing abetalipoproteinemia include:

1. **Dietary Modifications**:
- Adopt a low-fat diet to reduce the intake of long-chain fatty acids, as they cannot be properly absorbed.
- Include medium-chain triglycerides (MCTs) in the diet, which can be absorbed without needing lipoproteins.

2. **Vitamin Supplementation**:
- Take fat-soluble vitamins (A, D, E, and K) in water-soluble forms to prevent deficiencies, as these vitamins typically require proper fat absorption.

3. **Regular Medical Monitoring**:
- Have regular check-ups with a healthcare provider to monitor vitamin levels and overall health to adjust dietary and supplementation strategies as needed.

4. **Genetic Counseling**:
- Consider genetic counseling for family planning and to understand the inheritance pattern and risks for future offspring.

5. **Symptom Management**:
- Address individual symptoms such as gastrointestinal issues or neurological symptoms via targeted therapies as prescribed by a healthcare provider.

Participation in a support group for individuals with rare diseases can also provide emotional and social support.
Medication: For abetalipoproteinemia, treatment typically includes vitamin E supplementation to address deficiencies and manage symptoms. High doses of fat-soluble vitamins (A, D, E, K) are often prescribed. Additionally, a special diet low in long-chain fatty acids and rich in medium-chain triglycerides may be recommended. Regular monitoring and supportive care are crucial for managing this condition.
Repurposable Drugs: Abetalipoproteinemia is a rare inherited disorder affecting fat absorption and metabolism due to mutations in the MTTP gene, which encodes the microsomal triglyceride transfer protein. Currently, there are no widely recognized repurposable drugs specifically for treating abetalipoproteinemia. Management typically involves dietary modifications, including a low-fat, high-vitamin E diet, and supplementation of fat-soluble vitamins (A, D, E, and K) to address deficiencies and prevent complications.

If potential repurposable drugs are considered in the future, they would likely aim to enhance lipid absorption or compensate for the defective protein function. However, it is essential to consult with a healthcare provider or specialist for the most current and personalized treatment options.
Metabolites: For abetalipoproteinemia, the key metabolite associated with the condition is apolipoprotein B. This protein is crucial for the assembly and secretion of lipoproteins containing triglycerides and cholesterol. Deficiency or absence of apolipoprotein B leads to poor absorption of dietary fats and fat-soluble vitamins, resulting in metabolic disturbances. The condition can cause low levels of LDL cholesterol and fat-soluble vitamins such as vitamin E, vitamin A, and vitamin K.
Nutraceuticals: Abetalipoproteinemia is a rare genetic disorder affecting fat absorption and lipid metabolism. Nutraceuticals, such as vitamin E and other fat-soluble vitamins (A, D, and K), are often used as part of the management strategy to address deficiencies and mitigate symptoms. Nanotechnology-based delivery systems for these nutraceuticals are being researched to enhance their bioavailability and therapeutic efficacy, but their use is still largely experimental.
Peptides: Abetalipoproteinemia is a rare inherited disorder that affects the absorption and transport of dietary fats, cholesterol, and fat-soluble vitamins. It is caused by mutations in the MTTP gene, which encodes the microsomal triglyceride transfer protein necessary for the assembly and secretion of apolipoprotein B-containing lipoproteins. As a result, individuals with this condition have very low levels of low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) in their blood.

Peptides related to this disorder typically refer to the apolipoproteins, particularly apolipoprotein B (ApoB), which are essential components of lipoprotein particles. Due to the defect in lipoprotein assembly, patients may have deficiencies or functional impairments in these peptides, leading to the clinical manifestations of the disease.

Nanotechnology, such as nanoparticles or nanocarriers, has potential therapeutic applications in abetalipoproteinemia. These nanomaterials can be engineered to deliver specific drugs, supplements, or genetic material to correct the underlying molecular defects, improve nutrient absorption, and reduce associated symptoms. However, these applications are in the research and experimental stages and are not yet established as standard treatments.